Tunable Reversir™ compounds
The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.
1. A modified oligonucleotide comprising 8-15 linked nucleotides, wherein at most only three of the nucleotides are high affinity monomers, and wherein the modified oligonucleotide comprises a nucleotide sequence substantially complementary to positions 2-8 of an antisense strand of an siRNA, and one of the high affinity monomers in the modified oligonucleotide is base paired with the 6th nucleotide from the 5′-end of the antisense strand of the siRNA.
2. The modified oligonucleotide of claim 1 , wherein the high affinity monomer is an LNA.
3. The modified oligonucleotide of claim 2 , wherein the modified oligonucleotide comprises three LNA nucleotides.
4. The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide is a single-stranded oligonucleotide that is at least 90% complementary to the antisense strand.
5. The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide is fully complementary to the antisense strand.
6. The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleotide linkage.
7. The modified oligonucleotide of claim 6 , wherein internucleotide linkage is a phosphorothioate.
8. The modified oligonucleotide of claim 7 , wherein the modified oligonucleotide comprises not more than three or four phosphorothioate modifications.
9. The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide is conjugated with a ligand.
10. The modified oligonucleotide of claim 9 , wherein the ligand is
11. The modified oligonucleotide of claim 9 , wherein the ligand is conjugated to 3′-terminus of the compound.
12. The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide is conjugated with a ligand and the ligand is conjugated to a nucleotide with a deoxy sugar in the modified oligonucleotide.
13. The modified oligonucleotide of claim 12 , wherein said deoxy sugar is a 2′-deoxy ribose.
14. The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide comprises 9, 10 or 11 linked nucleotides.
15. The modified oligonucleotide of claim 1 , wherein only two of the nucleotides are high affinity monomers.
16. A kit comprising a modified oligonucleotide of claim 1 .
17. The kit of claim 16 , wherein the kit further comprises a siRNA.
18. A method or a system for assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease, the method comprising the steps of:
(1) treating all subjects with the pharmaceutical composition for a first treatment time frame,
(2) deriving mRNA level and/or physiological outcome measures for the all subjects,
(3) separating the responder members of the treated subjects from the non-responder members,
(4) randomizing and stratifying members of the responders into at least two further sub-groups,
(5) continue treating members of one sub-group in (4) with the pharmaceutical composition, and treating members of the other sub-group with a modified oligonucleotide of claim 1 for a second treatment timeframe,
(6) deriving mRNA level and/or physiological outcome measures for the sub-groups,
(7) comparing the outcomes at (6) with the outcomes at (2),
(8) using the comparison in (7) to derive an efficacy and safety measures for the pharmaceutical composition wherein the pharmaceutical composition is an oligonucleotide.
19. A method or a system for assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease, the system comprising the steps of:
(1) stratifying a subject group into at least two sub-groups,
(2) treating members of one sub-group with the pharmaceutical composition for a first treatment timeframe, and treating members of a second sub-group with a blinded placebo,
(3) deriving mRNA level, and/or biomarker and/or physiological outcome measures for the sub-groups,
(4) treating members of the treated sub-group with a modified oligonucleotide of claim 1 , and treating members of the other blinded placebo sub-group with the pharmaceutical composition for a second treatment timeframe,
(5) deriving mRNA level and/or physiological outcome measures for the sub-groups,
(6) comparing the outcomes at (5) with the outcomes at (3),
(7) using the comparison in (6) to derive an efficacy and safety measures for the pharmaceutical composition wherein the pharmaceutical composition is an oligonucleotide.